Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

This study tests a virus-based treatment (TILT-123) combined with the immunotherapy drug pembrolizumab, or combined with a chemotherapy drug (liposomal doxorubicin), for women with ovarian cancer that has stopped responding to standard platinum-based chemotherapy. **You may be eligible if...** - You are a woman over 18 with confirmed ovarian, fallopian tube, or primary peritoneal cancer - Your cancer stopped responding to or progressed during platinum chemotherapy - You have received no more than one prior chemotherapy regimen in the platinum-resistant/refractory setting (for Phase Ib) - You are willing and able to consent **You may NOT be eligible if...** - Your cancer still responds to platinum chemotherapy - You have had more lines of prior chemotherapy than allowed - You have serious organ dysfunction or uncontrolled infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.